B-cell maturation antigen (BCMA) is a protein, also called tumor necrosis factor receptor superfamily member 17 (TNFRSF17) or CD269 antigen, which is encoded in humans by TNFRSF17 gene. BCMA is an essential member of tumor necrosis factor receptor super family and is preferentially expressed in B lymphocytes. B-cell maturation antigen receptor is necessary for B-cell development and also in autoimmune response. This receptor specially binds to tumor necrosis factor (TNF) super family member 13b. BCMA or TNFRSF17 binds to TNF and activates NF-kappaB and MAPK8/JNK. TNFRSF17 also binds with other TRAF family members and may conduct or transfer signals for cell proliferation and survival. It is a receptor for TALL-1, and activates NF-kappaB through a NIK-, TRAF5-, IKK-, and TRAF6- dependent pathway. For TALL-1, TNFRSF17 is identified as NF-kappaB activating receptor by targets for drug development against certain autoimmune diseases or immunodeficient. BCMA works as a target of donor B-cell immunity in patients with myeloma who respond to donor lymphocyte infusions (DLI). BCMA may contribute rejection of tumor in vivo as the response of antibody to the cell surface. Recent study suggests that BCMA is effective against cells with multiple myeloma (MM). It is a deadly disease of plasma cells, which needs some mediation by clinical researchers.
Middle-aged men who have a past history of monoclonal gammopathy have highest risk of developing multiple myeloma with the exposure of chemicals or radiations. It is important to increase awareness about effective treatment of cancer and related diseases among the research community to provide major restraint for increase in BCMA targeted treatment market in future. Rise in prevalence of multiple myeloma globally is expected to boost the expansion of the BCMA targeted therapies market in the near future. Multiple myeloma can be fatal and can recur with other associated serious complications. Prevalence of multiple myeloma and other serious fatal diseases needs specific diagnosis and targeted treatment at the global level. Therefore, there is an immediate requirement of effective therapies and medical care, which is likely to fuel the expansion of the BCMA market in near future.
The global BCMA targeted therapy market can be segmented into product type, end-user, and region. In terms of product type, the market can be segmented into CAR-T cells, bispecific antibodies, and antibody drug conjugates. These are the different kind of products related to B-cell maturation antigen based on mechanism or function perform with other proteins or cells of body as identification and destruction of tumor cell lysis of malignant multiple myeloma and conjugate formation with antibodies. In terms of end-user, the global BCMA targeted therapies market can be segmented into hospitals and cancer research institutes. In terms of geography, the market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Key players operating in the BCMA targeted therapies market are Celgene Corporation, Bluebird Bio, Poseida Therapeutics, Inc., Juno Therapeutics, and Eureka Therapeutics. Several stakeholders have entered the market for development of novel therapy. They provide funds for research and development of BMCA targeted therapy in both clinical and commercial research space. Some clinical stage products that have emerged out of such collaborations include BCMA-CART (Abramson Cancer Center of the University of Pennsylvania and Novartis) and bb2121 (Celgene and Bluebird Bio).
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.